scholarly journals New Frontiers in the Diagnosis and Treatment of Chronic Neutrophilic Lung Diseases

10.5772/53834 ◽  
2013 ◽  
Author(s):  
T. Andrew ◽  
Amit Gaggar ◽  
Matthew T.
Keyword(s):  
Lung Diseases ◽  
Diagnosis And Treatment

Chronic fibrosing progressing interstitial lung disease: a decision of Multidisciplinary Expert Board

2021 ◽  
Vol 31 (4) ◽  
pp. 505-510
Author(s):  
S. N. Avdeev ◽  
S. Yu. Chikina ◽  
I. E. Tyurin ◽  
A. S. Belevskiy ◽  
S. A. Terpigorev ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Function ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Disease ◽  
Russian Federation ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Diagnosis And Treatment ◽  
Antifibrotic Therapy

Introduction. The natural course of some interstitial lung diseases (ILD) is characterized by progressive fibrosing phenotype resembling idiopathic pulmonary fibrosis (IPF). Until recently, the antifibrotic drug nintedanib was approved for treatment of the only fibrosing ILD which was IPF. A new indication for this drug which has been registered in Russian Federation in 2021 includes other fibrosing ILDs with progressive phenotype (PF-ILDs) and ILD associated with systemic scleroderma (SS-ILD).The aim of this publication is to describe general considerations of the decision of Multidisciplinary Expert Board on diagnosis and treatment of PF-ILDs including SS-ILD.Results. According to the extension in nintedanib use mentioned above, the Expert Board created an algorithm for diagnosis and treatment of patients with PF-ILDs and criteria for nuntedanib administration in PF-ILDs.Conclusion. Antifibrotic therapy is needed for patients with PF-ILDs with the failure of the stanrard therapy. In those patients antifibrotic treatment should be initiated as early as possible to better preserve the lung function.

scholarly journals FRESH AIR: an implementation research project funded through Horizon 2020 exploring the prevention, diagnosis and treatment of chronic respiratory diseases in low-resource settings

2016 ◽  
Vol 26 (1) ◽  
Author(s):  
Liza Cragg ◽  
◽  
Siân Williams ◽  
Niels H Chavannes
Keyword(s):  
Lung Diseases ◽  
Respiratory Diseases ◽  
Research Programme ◽  
Diagnosis And Treatment ◽  
Global Network ◽  
Kyrgyz Republic ◽  
Science Project ◽  
Horizon 2020 ◽  
Chronic Respiratory Diseases ◽  
Chronic Lung Diseases

Abstract This protocol describes FRESH AIR, an implementation science project exploring how to improve the prevention, diagnosis and treatment of chronic lung diseases in contexts with limited healthcare resources. It consists of inter-related studies that take place in four countries that are part of the International Primary Care Respiratory Group’s (IPCRG) global network: Uganda, the Kyrgyz Republic, Vietnam and Greece. The project has been funded by the European Commission Horizon 2020 research programme and runs from October 2015 until September 2018.

Chronical bronchitis

1980 ◽  
Vol 61 (4) ◽  
pp. 1-5
Author(s):  
A. N. Kokosov ◽  
N. I. Aleksandrova
Keyword(s):  
Chronic Bronchitis ◽  
Lung Diseases ◽  
Clinical Course ◽  
Diagnosis And Treatment

The modern views on the etiology and pathogenesis of chronic bronchitis, the most common form of chronic nonspecific lung diseases, are presented. On the basis of long-term observations and generalization of the latest literature data, the features of the clinical course of this disease are characterized. Methods of diagnosis and treatment are described.

scholarly journals ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly

2020 ◽  
Vol 6 (4) ◽  
pp. 00143-2020
Author(s):  
Clairelyne Dupin ◽  
Vânia Fernandes ◽  
Fernanda Hernandez-Gonzalez ◽  
Sebastiano Emanuele Torrisi ◽  
Tiago M. Alfaro ◽  
...  
Keyword(s):  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Diagnosis And Treatment ◽  
International Congress ◽  
European Respiratory Society ◽  
Idiopathic Interstitial Pneumonias ◽  
Diffuse Parenchymal Lung Diseases ◽  
Origin Group ◽  
Selection Of ◽  
Parenchymal Lung

This article discusses a selection of the scientific presentations in the field of interstitial lung diseases (ILDs) that took place at the 2019 European Respiratory Society International Congress in Madrid, Spain. There were sessions from all four groups within Assembly 12: group 12.01 “Idiopathic interstitial pneumonias”, group 12.02 “ILDs/diffuse parenchymal lung diseases (DPLDs) of known origin”, group 12.03 “Sarcoidosis and other granulomatous ILDs/DPLDs” and group 12.04 “Rare ILDs/DPLDs”. The presented studies brought cutting-edge developments on several aspects of these conditions, including pathogenesis, diagnosis and treatment. As many of the ILDs are individually rare, the sharing of experiences and new data that occur during the Congress are very important for physicians interested in ILDs and ILD patients alike.

scholarly journals ALPHA-1-ANTITRYPSIN DEFICIENCY IN CHILDREN

2017 ◽  
pp. 166-170
Author(s):  
S. I. MELNIK ◽  
M. V. PINEVSKAYA ◽  
E. A. ORLOVA ◽  
S. V. STAREVSKAYA ◽  
I. Y. MELNIKOVA ◽  
...  
Keyword(s):  
Enzyme Replacement Therapy ◽  
Replacement Therapy ◽  
Lung Diseases ◽  
Hereditary Disease ◽  
Diagnosis And Treatment ◽  
Enzyme Replacement ◽  
Antitrypsin Deficiency ◽  
Leading Position ◽  
Alpha 1 Antitrypsin Deficiency ◽  
Alpha 1 Antitrypsin

Hereditary deficiency of the alpha-1-antitrypsin occupies a leading position among the causes of chronic nonspecific lung diseases with emphysema formation. Deficiency of alpha-1-antitrypsin is a potentially fatal hereditary disease, under-diagnosed by physicians of various specialities. The authors familiarize pediatricians with this hereditary disease, difficulties of its diagnosis and treatment. There are presented own author`s data on the diagnosis and the experience of the enzyme replacement therapy of alpha-1-antitrypsin deficiency with the drug INN «Alpha-1 antitrypsin human» (Respikam).

scholarly journals Organisation of diagnosis and treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases in the Nordic countries

2015 ◽  
Vol 2 (1) ◽  
pp. 28348 ◽  
Author(s):  
Elisabeth Bendstrup ◽  
Charlotte Hyldgaard ◽  
Alan Altraja ◽  
Tone Sjåheim ◽  
Marjukka Myllärniemi ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Nordic Countries ◽  
Diagnosis And Treatment

Barriers to the Diagnosis and Treatment of Interstitial Lung Diseases (ILD) in Colombia

2019 ◽  
Author(s):  
O.M. Garcia Morales ◽  
J.L. Galindo ◽  
D.L. Rey Sanchez ◽  
C.A. Celis-Preciado ◽  
A. Cañas
Keyword(s):  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Diagnosis And Treatment
Sign in / Sign up

Export Citation Format

Share Document